Cingulate Inc. Common Stock
CINGCingulate Inc. is a biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders. It specializes in creating novel treatments targeting conditions such as depression, anxiety, and pain, leveraging its expertise in brain chemistry and drug delivery.
Company News
Cingulate Inc. placed CEO Shane J. Schaffer on administrative leave due to unrelated legal matters. Jennifer Callahan was appointed interim CEO, retaining her CFO role, while board member Jay Roberts became Executive Chairman to ensure business continuity.
Allarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.
Cingulate Inc. reported positive results for its lead ADHD asset CTx-1301, including successful completion of Phase 3 trials and plans to submit a New Drug Application in mid-2025. The company also strengthened its balance sheet through various financing activities.
Cingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.
Cingulate Inc. announced that it was issued a European patent for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent will cover up to 30 European territories, including the United Kingdom.
